Plavix patent upheld by Federal Circuit
22 December 2008
Eileen McDermott, New York
The US Court of Appeals for the Federal Circuit has upheld a US patent for the popular blood clot-inhibitor Plavix in another victory for branded pharmaceutical companies
A three-judge panel last week affirmed the US District Court for the Southern District of New York's June 2007 ruling in favour of Bristol-Myers Squibb and Sanofi Aventis, which held that US patent number 4,847,265 was valid and enforceable.
The '265 patent covers clopidogrel bisulfate, a blood thinner and the active ingredient in Plavix.
The decision stems...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial